LYRA
NASDAQ · Pharmaceuticals
Lyra Therapeutics Inc
$0.73
-0.02 (-2.67%)
Financial Highlights (FY 2026)
Revenue
2.12M
Net Income
-129,081,057
Gross Margin
—
Profit Margin
-6,090.9%
Rev Growth
+74.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 60.3% | 60.3% |
| Operating Margin | -6,280.8% | -5,652.7% | 33.2% | 29.0% |
| Profit Margin | -6,090.9% | -5,786.4% | 24.8% | 19.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.12M | 1.22M | 681.7K | 558.5K |
| Gross Profit | — | — | 411.1K | 336.8K |
| Operating Income | -133,101,465 | -68,750,756 | 226.6K | 162.2K |
| Net Income | -129,081,057 | -66,674,099 | 169.3K | 107.5K |
| Gross Margin | — | — | 60.3% | 60.3% |
| Operating Margin | -6,280.8% | -5,652.7% | 33.2% | 29.0% |
| Profit Margin | -6,090.9% | -5,786.4% | 24.8% | 19.3% |
| Rev Growth | +74.2% | +74.2% | +3.7% | -9.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.04M | 1.08M |
| Total Equity | — | — | 1.55M | 1.59M |
| D/E Ratio | — | — | 0.67 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -132,454,747 | -72,217,636 | 337.6K | 271.6K |
| Free Cash Flow | — | — | 110.0K | 71.2K |